EWA
PLX icon

EverSource Wealth Advisors’s Protalix BioTherapeutics PLX Stock Holding History

EverSource Wealth Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$380 Buy
163
+152
+1,382% +$322 ﹤0.01% 4172
2026
Q1 		$24 Buy
+11
New +$27 ﹤0.01% 4354

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

EverSource Wealth Advisors's PLX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Protalix BioTherapeutics (PLX) stake by 1,382% in Q2 2026, buying an estimated $322 and bringing the position to 163 shares worth $380. The position accounts for ﹤0.01% of the portfolio, ranked #4172.

EverSource Wealth Advisors first reported a position in PLX in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • EverSource Wealth Advisors held 163 shares of Protalix BioTherapeutics worth $380 as of Q2 2026.
  • EverSource Wealth Advisors bought 152 Protalix BioTherapeutics shares in Q2 2026, an estimated $322.
  • Protalix BioTherapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4172 holding.
  • EverSource Wealth Advisors first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.